Prolongation of allograft survival by artemisinin treatment is associated with blockade of OX40-OX40L

References

• Bierer BE, Holländer G, Fruman D, et al. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol. 1993;5(5):763–773.
   PubMed Web of Science ®Google Scholar
• Dangoor JY, Hakim DN, Singh RP, et al. Transplantation: a brief history. Exp Clin Transplant. 2015;13(1):1–5.
   PubMed Web of Science ®Google Scholar
• Ilyas M, Colegio OR, Kaplan B, et al. Cutaneous toxicities from transplantation-related medications. Am J Transplant. 2017;17(11):2782–2789.
   PubMed Web of Science ®Google Scholar
• Young BA, Marsh CL, Alpers CE, et al. Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis. 1996;28(4):561–571.
   PubMed Web of Science ®Google Scholar
• Ivulich S, Westall G, Dooley M, et al. The evolution of lung transplant immunosuppression. Drugs. 2018;78(10):965–982.
   PubMed Web of Science ®Google Scholar
• Reuberson J, Horsley H, Franklin RJ, et al. Discovery of a potent, orally bioavailable PI4KIIIβ inhibitor (UCB9608) able to significantly prolong allogeneic organ engraftment in vivo. J Med Chem. 2018;61(15):6705–6723.
   PubMed Web of Science ®Google Scholar
• Marino J, Paster J, Benichou G. Allorecognition by T lymphocytes and allograft rejection. Front Immunol. 2016;7:582.
   PubMed Web of Science ®Google Scholar
• Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant. 2008;13(4):438–444.
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Tatapudi VS, Leffell MS, et al. HLA in transplantation. Nat Rev Nephrol. 2018;14(9):558–570.
   PubMed Web of Science ®Google Scholar
• Schroder PM, Fitch ZW, Schmitz R, et al. The past, present, and future of costimulation blockade in organ transplantation. Curr Opin Organ Transplant. 2019;24(4):391–401.
   PubMed Web of Science ®Google Scholar
• Dai Z, Lakkis FG. The role of cytokines. CTLA-4 and costimulation in transplant tolerance and rejection. Curr Opin Immunol. 1999;11(5):504–508.
   PubMed Web of Science ®Google Scholar
• Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009;9(4):271–285.
   PubMed Web of Science ®Google Scholar
• Ishii N, Takahashi T, Soroosh P, et al. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol. 2010;105:63–98.
   PubMed Web of Science ®Google Scholar
• So T, Lee SW, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008;19(3-4):253–262.
   PubMed Web of Science ®Google Scholar
• Weinberg AD, Evans DE, Thalhofer C, et al. The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J Leukoc Biol. 2004;75(6):962–972.
   PubMed Web of Science ®Google Scholar
• Pejman S, Shouji I, Kazuo S, et al. Differential requirements for OX40 signals on generation of effector and central memory CD4+ T cells. J Immunol. 2007;179(8):5014–5023.
   PubMed Web of Science ®Google Scholar
• Lau LL, Jamieson BD, Somasundaram T, et al. Cytotoxic T-cell memory without antigen. Nature. 1994;369(6482):648–652.
   PubMed Web of Science ®Google Scholar
• Ariel A, Lider O, Brill A, et al. Induction of interactions between CD44 and hyaluronic acid by a short exposure of human T cells to diverse pro-inflammatory mediators. Immunology. 2000;100(3):345–351.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen D, Nie GD, et al. CD8(+)CD122(+) T-cells: a newly emerging regulator with central memory cell phenotypes. Front Immunol. 2015;6:494.
   PubMed Web of Science ®Google Scholar
• Yuan X, Salama DA, Dong V, et al. The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol. 2003;170(6):2949–2955.
   PubMed Web of Science ®Google Scholar
• Ivetic A, Hoskins Green HL, et al. L-selectin: a major regulator of leukocyte adhesion, migration and signaling. Front Immunol. 2019;10:1068.
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457.
   PubMed Web of Science ®Google Scholar
• Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity. 2019;50(4):812–831.
   PubMed Web of Science ®Google Scholar
• Heink S, Yogev N, Garbers C, et al. Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells. Nat Immunol. 2017;18(1):74–85.
   PubMed Web of Science ®Google Scholar
• Fogal B, Yi T, Wang C, et al. Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. J Immunol. 2011;187(12):6268–6280.
   PubMed Web of Science ®Google Scholar
• Choi J, Aubert O, Vo A, et al. Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients. Am J Transplant. 2017; 17(9):2381–2389.
   PubMed Web of Science ®Google Scholar
• Hien TT, White NJ. Qinghaosu. Lancet. 1993;341(8845):603–608.
   PubMed Web of Science ®Google Scholar
• An J, Minie M, Sasaki T, et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu Rev Med. 2017;68:317–330.
   PubMed Web of Science ®Google Scholar
• Wu Y, He S, Bai B, et al. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation . Cell Mol Immunol. 2016;13(3):379–390.
   PubMed Web of Science ®Google Scholar
• Zhao YG, Wang Y, Guo Z, et al. Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol. 2012;189(9):4417–4425.
   PubMed Web of Science ®Google Scholar
• Flannery EL, Chatterjee AK, Winzeler EA. Antimalarial drug discovery – approaches and progress towards new medicines. Nat Rev Microbiol. 2013;11(12):849–862.
   PubMed Web of Science ®Google Scholar
• Germi R, Mariette C, Alain S, et al. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res. 2014;101:57–61.
   PubMed Web of Science ®Google Scholar
• Sabé N, González-Costello J, Oriol I, et al. Donor-transmitted malaria after heart transplant managed successfully with artesunate. Transpl Infect Dis. 2014;16(6):999–1002.
   PubMed Web of Science ®Google Scholar
• Yu L, Yan Y, Li S, et al. Induction and maintenance of T-dependent or T-independent xenotolerance by nonprimarily-vascularized skin or thymus grafts. Transplantation. 2005;79(5):520–527.
   PubMed Web of Science ®Google Scholar
• Arredouani MS, Kasran A, Vanoirbeek JA, et al. Haptoglobin dampens endotoxin-induced inflammatory effects both in vitro and in vivo. Immunology. 2005;114(2):263–271.
   PubMed Web of Science ®Google Scholar
• Li S, Yan Y, Lin Y, et al. Rapidly induced, T-cell independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells. Blood. 2007;110(12):3926–3935.
   PubMed Web of Science ®Google Scholar
• Willems L, Li S, Rutgeerts O, et al. IL-7 is required for the development of the intrinsic function of marginal zone B cells and the marginal zone microenvironment. J Immunol. 2011;187(7):3587–3594.
   PubMed Web of Science ®Google Scholar
• Kitchens WH, Dong Y, Mathews DV, et al. Interruption of OX40L signaling prevents costimulation blockade-resistant allograft rejection. JCI Insight. 2017;2(5):e90317.
   PubMed Web of Science ®Google Scholar
• Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med. 2008;205(13):3133–3144.
   PubMed Web of Science ®Google Scholar
• Booth AJ, Grabauskiene S, Wood SC, et al. IL-6 promotes cardiac graft rejection mediated by CD4+ cells. J Immunol. 2011;187(11):5764–5771.
   PubMed Web of Science ®Google Scholar
• Demirci G, Li XC. Novel roles of OX40 in the allograft response. Curr Opin Organ Transplant. 2008;13(1):26–30.
   PubMed Web of Science ®Google Scholar
• Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(3):312–332.
   PubMed Web of Science ®Google Scholar
• Zhang C, Gong MX, Qiu F, et al. Effects of arteannuin B, arteannuic acid and scopoletin on pharmacokinetics of artemisinin in mice. Asian Pac J Trop Med. 2016; 9(7):677–681.
   PubMed Web of Science ®Google Scholar
• Valenzuela NM, Schaub S. The biology of IgG subclasses and their clinical relevance to transplantation. Transplantation. 2018;102(1S Suppl 1):S7–S1.
   PubMedGoogle Scholar
• Wasowska B, Baldwin WM, 3rd, Howell DN, et al. The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG anti-donor class I alloantibody responses. Transplantation. 1993;56(3):672–680.
   PubMed Web of Science ®Google Scholar
• Patel K, Batty K, Moore B, et al. Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model. J Antimicrob Chemother. 2014;69(8):2155–2163.
   PubMed Web of Science ®Google Scholar
• Khakzad M, Ganji A, Ariabod V, et al. Artemisinin therapeutic efficacy in the experimental model of multiple sclerosis. Immunopharmacol Immunotoxicol. 2017; 39(6):348–353.
   PubMed Web of Science ®Google Scholar
• Jordan SC, Choi J, Kim I, et al. Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: therapeutic implications of IL-6 receptor blockade. Transplantation. 2017;101(1):32–44.
   PubMed Web of Science ®Google Scholar
• Wu Y, El Shikh ME, El Sayed RM, et al. IL-6 produced by immune complex-activated follicular dendritic cells promotes germinal center reactions, IgG responses and somatic hypermutation. Int Immunol. 2009;21(6):745–756.
   PubMed Web of Science ®Google Scholar
• Li X, Li TT, Zhang XH, et al. Artemisinin analogue SM934 ameliorates murine experimental autoimmune encephalomyelitis through enhancing the expansion and functions of regulatory T cell. PLoS One. 2013;8(8):e74108 29
   PubMed Web of Science ®Google Scholar
• Li Z, Shi X, Liu J, et al. Artesunate prevents type 1 diabetes in NOD mice mainly by inducing protective IL-4-producing T cells and regulatory T cells. Faseb J. 2019;33(7):8241–8248.
   PubMed Web of Science ®Google Scholar